Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2006 4
2008 1
2009 2
2010 1
2011 1
2012 1
2014 4
2015 3
2016 2
2017 3
2018 2
2020 3
2021 1
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: weitsman g. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.
Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen SH, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan JNE, Flores-Borja F, Barber PR, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley JA, Parsons M, Arnold JN, Ameer-Beg S, Quezada SA, Yarden Y, Sala G, Ng T. Vicencio JM, et al. Among authors: weitsman g. Cell Death Dis. 2022 Mar 28;13(3):274. doi: 10.1038/s41419-022-04701-3. Cell Death Dis. 2022. PMID: 35347108 Free PMC article.
Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients.
Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T. Weitsman G, et al. Biochem Soc Trans. 2014 Dec;42(6):1498-505. doi: 10.1042/BST20140165. Biochem Soc Trans. 2014. PMID: 25399560 Free PMC article. Review.
How Förster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology.
Fruhwirth GO, Fernandes LP, Weitsman G, Patel G, Kelleher M, Lawler K, Brock A, Poland SP, Matthews DR, Kéri G, Barber PR, Vojnovic B, Ameer-Beg SM, Coolen AC, Fraternali F, Ng T. Fruhwirth GO, et al. Among authors: weitsman g. Chemphyschem. 2011 Feb 25;12(3):442-61. doi: 10.1002/cphc.201000866. Epub 2011 Feb 15. Chemphyschem. 2011. PMID: 21328516 Review.
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V, Galazi M, Weitsman G, Monypenny J, Al-Salemee F, Barber PR, Ng K, Beatson R, Szokol B, Orfi L, Mullen G, Vanhaesebroeck B, Chowdhury S, Leung HY, Ng T. Gómez V, et al. Among authors: weitsman g. Mol Cancer Ther. 2022 Apr 1;21(4):667-676. doi: 10.1158/1535-7163.MCT-21-0320. Mol Cancer Ther. 2022. PMID: 35086953 Free PMC article.
A small molecule inhibitor of HER3: a proof-of-concept study.
Colomba A, Fitzek M, George R, Weitsman G, Roberts S, Zanetti-Domingues L, Hirsch M, Rolfe DJ, Mehmood S, Madin A, Claus J, Kjaer S, Snijders AP, Ng T, Martin-Fernandez M, Smith DM, Parker PJ. Colomba A, et al. Among authors: weitsman g. Biochem J. 2020 Sep 18;477(17):3329-3347. doi: 10.1042/BCJ20200496. Biochem J. 2020. PMID: 32815546 Free PMC article.
Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.
Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, Martin-Fernandez ML, Cameron A, Fraternali F, Ng T, Parker PJ. Claus J, et al. Among authors: weitsman g. Elife. 2018 May 1;7:e32271. doi: 10.7554/eLife.32271. Elife. 2018. PMID: 29712619 Free PMC article.
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.
Barber PR, Mustapha R, Flores-Borja F, Alfano G, Ng K, Weitsman G, Dolcetti L, Mohamed AA, Wong F, Vicencio JM, Galazi M, Opzoomer JW, Arnold JN, Thavaraj S, Kordasti S, Doyle J, Greenberg J, Dillon MT, Harrington KJ, Forster M, Coolen ACC, Ng T. Barber PR, et al. Among authors: weitsman g. Elife. 2022 Dec 23;11:e73288. doi: 10.7554/eLife.73288. Elife. 2022. PMID: 36562609 Free PMC article.
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Propper DJ, Gao F, Saunders MP, Sarker D, Hartley JA, Spanswick VJ, Lowe HL, Hackett LD, Ng TT, Barber PR, Weitsman GE, Pearce S, White L, Lopes A, Forsyth S, Hochhauser D. Propper DJ, et al. Among authors: weitsman ge. Br J Cancer. 2022 Nov 9. doi: 10.1038/s41416-022-02015-x. Online ahead of print. Br J Cancer. 2022. PMID: 36352028
33 results